Full text
| |
| Author(s): |
Elizabeth Bilevicius
Total Authors: 1
|
| Document type: | Doctoral Thesis |
| Press: | Campinas, SP. |
| Institution: | Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas |
| Defense date: | 2011-09-02 |
| Examining board members: |
Fernando Cendes;
Luiz Eduardo Betting;
Marilisa Mantovani Guerreiro;
Americo Ceiki Sakamoto;
Veriano Alexandre Junior
|
| Advisor: | Íscia Teresinha Lopes Cendes; Fernando Cendes |
| Abstract | |
The objective of the present work was to investigate the relationship between brain MRI and clinical characteristics and patterns of antiepileptic drug (AED) response in patients with mesial temporal lobe epilepsy (MTLE).In order to do that,one hundred sixty five MTLE patients were divided into seizure-free with AED (50 AEDresponders, 31 women), 87 pharmacoresistants (53 women), and 28 remitting-relapsing seizure control group (17 women). All groups were evaluated regarding age, frequency of seizures and age at epilepsy onset, duration of epilepsy, febrile seizures (FS), presence and side of hippocampal atrophy on visual inspection (HA), initial precipitating injuries (IPIs), type and quantity of AEDS used. The right and left hipoccampi from 99 patients belonging to all three groups (43 pharmacoresistants, 31 pharmacoresponsive and 25 remitting-relapsing subjects). were submitted to manual morphometry by DISPLAY software (Brain Imaging Centre, Montreal, Canada) as well as hipoccampi selected from 30 healthy controls. The calculated mean from those hipoccampi were compared within subjects and with controls. For gray matter (GM) MRI voxel-based morphometry (VBM) we selected only patients with unilateral HA on visual MRI analysis (n=100). Comparisons were made between all groups and 75 healthy controls. Age at epilepsy onset was lower (p=0,005) and initial frequency of seizures was higher in pharmacoresistants compared with the other two groups (p=0,018). The most used AEDS were carbamazepine and clobazam (always in association). The highest carbamazepine dose was observed in pharmacorresistants (p<0,001) and remitting-relapsing group (p=0,02). The highest dose of clobazam occurred only in pharmacoresistant group (p=0,017). The comparison between the mean hippocampi volumes from three groups and controls showed differences only on the pharmacoresistants left (p=0,004) and right(p=0,02) hippocampus comparing to controls. All groups showed GM atrophy compared to controls in ipsilateral hippocampus, bilateral parahippocampal gyri, frontal, occipital, parietal and cerebellar areas. In the AED-responders group such findings were more restricted to areas ipsilateral to the epileptic focus and more widespread in pharmacoresistants and remitting-relapsing groups. VBM pairwise comparisons showed areas with GM volume reduction in pharmacoresistants and remitting-relapsing compared with AED-responders in bilateral periorbital frontal (p< 0,01), cingulum (p<0,05), and temporal lobe contralateral to the epileptic focus (p< 0,05). We may conclude that, pharmacoresistants and remittingrelapsing patients presented a similar pattern of GM atrophy which was more widespread compared with AED-responders on VBM. We could also observe that age at epilepsy onset was lower (p=0,005) and initial seizure frequency was higher in pharmacoresistants (AU) | |